Techincal420 Deep Dive: Cannabics Pharmaceuticals (OTC:CNBX)

During the last year, we have seen a substantial spike of interest in the Israeli cannabis market, and this is a trend that is just getting started. We attribute the increased interest to the country overtaking Germany as the largest importer of medical cannabis and are bullish on this.

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a US company with R&D based in Israel and is considered a global leader in the development of cancer related cannabinoid-based therapies. For several years, we have been following the Israeli biotech company and believe the story is flying under the radar.

During the last year, Cannabics has reported several important milestones and we are following how the story advances from here. A few years ago, several key changes were made to the management team and we are favorable on the direction the business is heading under new leadership of CEO Eyal Barad and Presidnet & COO Gabriel Yariv.

At current levels, we believe that Cannabics has a favorable risk-reward profile and are following the opportunity for the following reasons:

1. Cannabics is executing on a strategy that is focused on creating a portfolio of valuable intellectual property (IP) and is working to have patents approved in several key markets
2. During the last year, the company has reported a series of important developments and we are favorable on how the business has advanced
3. We believe Cannabics has significant potential catalysts for growth and believe the market is not taking this potential into account
4. The management team is focused on creating value for shareholders and has been working to cut costs and execute on core growth initiatives
5. At current levels, we believe Cannabics has a compelling valuation and believe the market underappreciates the potential value that can be created by the business

Download Your Complete Copy Of The Report Now

About Cannabics Pharmaceuticals

Cannabics Pharmaceuticals is a global leader in the development of cancer related cannabinoid-based medicine. The company is licensed by the Israeli Ministry of Health to conduct scientific and clinical research on cannabinoid formulations for cancer.

2021 has been a banner year for Cannabics and we are favorable on the developments that have been reported so far. Over the next year, we expect the company to build on its recent success and are favorable on the direction the business is going.

Israel is known for having state-of-the-art medical programs and we believe that Cannabics has benefited from this by attractive valuable human capital. The company is focused on developing treatments for major indications and we are favorable on the amount of value that is associated with its pipeline of therapies that are in various stages of pre-clinical and clinical studies.

Pursuant to an agreement between StoneBridge Partners LLC and Cannabics Pharmaceuticals Inc. (CNBX) we have been hired for a period of 30 days beginning June 7, 2021 and ending July 7, 2021 to publicly disseminate information about (CNBX) including on the Website and other media including Facebook and Twitter. We are being paid $5,000 per month (CBNX) for or were paid “0” shares of restricted common shares. We own zero shares of (CNBX), which we purchased in the open market. We plan to sell the “ZERO” shares of (CNBX) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (CNBX) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Share

Tags

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Top Stories